Reports Q1 revenue $828,000, consensus $1.54M. “We are now better positioned than ever to capitalize on EsoGuard’s significant clinical and commercial opportunity,” said Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer. “We continue to make strong progress on multiple fronts – expanding our cash-pay and contracted programs targeting concierge medicine practices and self-insured employers, while also gaining traction with regional commercial insurers for EsoGuard coverage. With additional capital secured, we have extended our operational runway well beyond key upcoming reimbursement milestones, including Medicare. This positions us to accelerate commercialization efforts once these milestones are achieved.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
- Lucid Diagnostics’ EsoGuard DNA Test shows cancer detection efficacy in study
- Lucid Diagnostics price target raised to $7.50 from $7 at Ascendiant
- Lucid Diagnostics Closes $16.1 Million Public Offering
- Lucid Diagnostics: Strong Buy Rating Backed by Growth Potential and Competitive Edge in EsoGuard Testing
- Lucid Diagnostics Announces Public Stock Offering